Adjuvant Hormonal Therapy in Premenopausal Women With Operable Breast Cancer: Not-So-Peripheral Perspectives

April 15, 2010
Richard R. Love, MD, MS

Oncology, ONCOLOGY Vol 24 No 4, Volume 24, Issue 4

While optimal adjuvant hormonal therapies for premenopausal women with operable breast cancer have yet to be defined, discussions and reviews of the state of the art and “areas of confusion” often fail to consider developments that are germane to keeping evidence-based clinical practice truly up-to-date.

Reviews of issues around adjuvant hormonal therapies for breast cancer in premenopausal women often focus on recent and current large clinical trials, and fail to address other subjects that are very germane to evidence-based and investigatory clinical practice. These topics include: (1) the descriptive epidemiology of breast cancer globally, (2) critical issues in tumor hormone receptor testing, (3) compelling data demonstrating that hormone receptor–positive breast cancer is a chronic disease, (4) data supportive of combined hormonal therapy with tamoxifen as the standard of care, and the limited justifications for awaiting the SOFT and TEXT trial results, (5) pharmacogenetic hypotheses with tamoxifen, (6) ethical issues in ovarian suppression vs ablative treatment, and (7) emerging data about the importance of primary tumor removal surgery itself and “surgical stress” in solid tumor management.

While optimal adjuvant hormonal therapies for premenopausal women with operable breast cancer have yet to be defined, discussions and reviews of the state of the art and “areas of confusion” often fail to consider developments that are germane to keeping evidence-based clinical practice truly up-to-date. The current communication is prompted by this perspective and a recent review and its commentaries.[2]

The late Jonathan Mann often said that the way we frame issues dictates how we approach them. Framing the challenges of getting to more effective adjuvant therapies for premenopausal women with hormone receptor–positive tumors within the context of our most recent and ongoing larger clinical trials only-which is what is usually done-is to ignore the richness and relevance of other provocative and emerging data that are directly applicable to clinical and investigative practice now. Here, I review such data in seven areas.

Descriptive Epidemiologic Data of Breast Cancer Globally

There are several reasons why we need to move away from perspectives and data based on North America only (or high-income countries only) in discussing breast cancer management. First, the cancer treatment and reading community is global, and we are increasingly called upon to be global citizens and speak to the needs of patients everywhere. In 2010, we will move to situations in which, worldwide, the majority of new annual cases of breast cancer will develop in Asian women (~800,000 of 1.5 million) and half will be in poor premenopausal women (~740,000 vs 44,000 premenopausal cases in the United States).[3,4]

Further, the fact that the overwhelming majority of our treatment data come from studies in women of northern European genetic background-with likely very specific tumor gene profiles and certainly different metabolic gene profiles-make the available data of uncertain relevance to this new majority of affected women who live in non-Western countries, as well as those women in Western countries of different genetic/ethnic backgrounds.[5-7] Finally, a common perception is that hormone receptor–positive breast cancer is less frequent in pre- than in postmenopausal women, but data from the Philippines, Vietnam, Taiwan, and China do not support this general conclusion.[8,9, and personal communications from Zhi Ming Shao, November 7, 2009; and from Ta Van To, May 2009]

In sum, our discussions about breast cancer management need to be more broadly sensitive and considerate of the global realities.

Tumor Hormonal Receptor Testing

While for some time there have been expressions of concern regarding quality control issues surrounding tumor hormonal receptor testing, the implications for practicing clinicians (and possible remedial actions) have not been obvious. With the upcoming publication of the American Society of Clinical Oncology (ASCO)–College of American Pathologists (CAP) guidelines on hormonal receptor quality assurance, this situation should change. In the meantime, various data regarding one broad issue, which will be addressed in the guidelines, deserve all clinicians’ attention: choices of tissue specimens and their management prior to laboratory testing.

The relevant data include time to penetration and fixation of subsequently tested tumor tissues (optimally < 30 minutes), pH of fixative (optimally neutral, not acidic), and duration of fixation (optimally > 8–10 hours; less critically < 48 hours). Each of these factors influence determination of the presence and levels of hormonal receptor proteins.[10-12] Inattention to these parameters leads to more frequent findings of hormone receptor–negative tumors and lower levels of hormonal receptor proteins. When hormonal receptor determinations are done on core biopsy specimens, approximately 10% more tumors are found to be hormone receptor–positive, compared with when tests are done on subsequent mastectomy (and lumpectomy?) specimens.[13,14] The implications of these findings are clear:

• False-negative findings of hormonal receptor protein lead to depriving patients of important, recurrence-preventing hormonal therapies and in many circumstances choices of usually more toxic chemotherapy treatments.

• Clinicians need to be involved in the complete management sequence of tissue specimens obtained when hormonal receptor testing is part of the diagnostic panel.

• The diagnostic sequence for breast masses may, in some circumstances, need reconsideration. When the sequence includes a fine-needle aspiration biopsy, and hormonal receptor determinations are then done on subsequent mastectomy (as practiced in most of the world) or lumpectomy specimens, even greater attention to tissue management procedures is warranted. The case for core biopsy as the first diagnostic procedure, with this specimen used for hormonal receptor testing and with associated attention to optimal tissue management, deserves renewed consideration.

Hormone Receptor–Positive Breast Cancer as a Chronic Disease

Data from multiple sources are reinforcing what clinicians have been aware of for some time, but this awareness has not yet completely translated into thoughtful clinical practice and investigative medicine. For example:

• Measurable and steady rates of recurrence characterize meta-analysis populations of patients with hormone receptor–positive breast cancer (more so than those with hormone receptor–negative tumors) through 15 years after diagnosis.[15,16] There is a lag in return to higher rates of recurrence in the immediate years after hormonal therapies are stopped (eg, ~5 years).[15,17-19]

• In cases where hormonal therapies are given for longer than 5 years or started after 5 years from diagnosis, lower rates of recurrence occur in the 5- to 10-year postdiagnosis window.[17,20-22]

Current National Comprehensive Cancer Network (NCCN) guidelines suggest the use of adjuvant hormonal therapy with an aromatase inhibitor after 5 years (ie, for postmenopausal women, a status that all premenopausal women can achieve with chemotherapies, ovarian ablation, or continuing suppression therapies). However, there does not appear to be a consensus on this recommendation, at least as manifested in recommendations for therapies after 5 years in ongoing adjuvant studies. Clearly, there are many uncertainties about risks and benefits for subsets of patients, but the clear conclusion that hormone receptor–positive breast cancer is, for many (and perhaps the majority of patients), a chronic disease, must command more of our collective attention. Part of the reticence to more frequently and forthrightly consider this issue comes from the fact that patients find this to be an upsetting perspective, particularly because this is not how the disease has been framed in the past.

Combined Ovarian Suppression/Ablation and Tamoxifen Therapy as the Standard of Care

In 2003–2004, it may have been reasonable to assert that tamoxifen alone was the hormonal therapy standard of care for premenopausal women with hormone receptor–positive tumors. This was the conclusion of the Suppression of Ovarian Function Trial (SOFT) investigators, who assessed tamoxifen vs ovarian function suppression or ablation plus tamoxifen vs ovarian function suppression or ablation plus an aromatase inhibitor (exemestane [Aromasin]), giving each therapy for 5 years.[2] Many in the research community have continued to maintain that tamoxifen alone is the standard of care in this setting.

Austrian investigators reporting on the issue of ovarian suppression plus tamoxifen or an aromatase inhibitor (trial discussed below), whose study began accrual in 1999, apparently did not consider tamoxifen alone to be the standard of care a decade ago.[23] In 2009–2010, however, it is neither reasonable nor appropriate to assert (1) such equivalence of tamoxifen alone and combined therapy, and (2) to call for continued accrual to SOFT and the Tamoxifen/Exemestane Trial (TEXT), withholding judgment on the role of aromatase inhibitors in combined therapy until these trials report their results. The following findings support these contentions:

• In metastatic hormone receptor–positive disease, four individual trials and a meta-analysis have demonstrated improved outcomes with combined ovarian suppression plus tamoxifen therapy over either therapy alone.[24,25]

• In a large Intergroup trial, luteinizing hormone-releasing hormone (LHRH) alone after CAF chemotherapy (cyclophosphamide, doxorubicin [Adriamycin], fluorouracil [5-FU]), was inferior to LHRH plus tamoxifen (disease-free survival difference at 9 years = 8%; overall survival difference at 9 years = 3%).[26] In the metastatic setting, LHRH alone and tamoxifen alone appear to be equivalent therapies.[27]

• Meta-analysis of adjuvant data suggests that the combination of LHRH plus tamoxifen is better than tamoxifen alone.[28]

• In the Intergroup adjuvant trial, oophorectomy plus tamoxifen produced a disease-free survival rate of 90.3%, compared to 87.8% for tamoxifen alone.[29]

• In two European adjuvant trials, LHRH plus tamoxifen was superior to six cycles of IV CMF chemotherapy (cyclophosphamide, methotrexate, 5-FU), while LHRH alone was equivalent to six cycles of Bonadonna CMF chemotherapy.[30,31]

• In the author’s adjuvant trial of oophorectomy plus tamoxifen, this strategy resulted in a risk reduction of 0.58; in the meta-analysis of trials assessing adjuvant tamoxifen alone in premenopausal women, the risk reduction was 0.42.[15,19]

The consistency of the evidence-although mostly indirect-and the logic that two mechanisms of action are functioning with combined therapy, make the superiority of combined ovarian suppression plus tamoxifen therapy difficult to ignore.

The repeated counterargument is that direct evidence is needed, and the SOFT and TEXT trials will provide this. For the two hypotheses under investigation in those trials, this argument deserves careful scrutiny. However, compelling direct evidence is already available. Gnant et al presented survival data from the Austrian Breast and Colorectal Cancer Study Group (ABCSG)-12 trial comparing LHRH plus anastrozole (Arimidex) and LHRH plus tamoxifen with or without zoledronic acid (Zometa) in premenopausal women with hormone receptor–positive breast cancer.[23] A 2×2 factorial design was used (1:1:1:1), with patients randomized to LHRH plus either anastrozole or tamoxifen, with or without zoledronic acid. The study enrolled 1,803 patients and was designed to test two primary hypotheses for the outcome of disease-free survival: (1) anastrozole against tamoxifen, and (2) zoledronic acid against no zoledronic acid.

While the addition of zoledronic acid exhibited a significant benefit in terms of disease-free survival, no difference in disease-free survival was found between the anastrozole and tamoxifen groups (P = .59, hazard ratio [HR] = 1.10, 95% confidence interval [CI] = 0.78–1.53). A similar pattern was seen for recurrence-free survival (P = .53, HR = 1.11, 95% CI = 0.80–1.56), and a trend for overall survival was found in favor of tamoxifen (P = .07, HR=1.80, 95% CI: 0.95–3.38).[23] While a failure to reject the null hypothesis in a trial designed to test for superiority does not allow us to conclude the treatments are equivalent, there is no evidence from these data to support the superiority of anastrozole over tamoxifen in this population. However, given the size of this trial, the maturity of the data (median follow up of 48 months), and the pattern and trend of results, there is little justification for the position that the superiority of anastrozole compared with tamoxifen after ovarian ablation or with ovarian suppression alone remains an open question.

Thousands of further patients and years of follow-up will be required to demonstrate even a small effect, and these Gnant results would have to be considered in reaching conclusions about the “true” comparison results. Both the SOFT and TEXT trials also allow chemotherapy treatment. Looking to these trials for a different answer to the question of aromatase inhibitor or tamoxifen superiority in premenopausal women whose ovarian function is stopped, is neither appropriate nor realistic. While a definitive conclusion cannot be drawn from the Gnant study in terms of the survival benefits of anastrozole over tamoxifen in the premenopausal setting, a reasonable decision is to proceed as though the treatment results are similar.

Pharmacogenetic Hypotheses About Tamoxifen

The role of metabolic activation in tamoxifen activity was recognized in the 1970s, when the minor metabolite of tamoxifen, 4-hydroxytamoxifen, was shown to have 100-fold greater affinity than tamoxifen toward estrogen receptors and subsequently 30- to 100-fold greater potency than tamoxifen in suppressing estrogen-dependent cell proliferation.[32] However, the contribution of this metabolite to the overall clinical effect of tamoxifen has remained unclear because its plasma concentrations are relatively low compared with those of tamoxifen or some of its other metabolites.

Our knowledge of the link between tamoxifen metabolism and response expanded rapidly subsequent to the characterization of another active metabolite, N-desmethyl 4-hydroxy-tamoxifen (endoxifen), by Indiana University investigators 7 years ago.[33,34] A series of laboratory studies carried out to characterize its pharmacology have now established that endoxifen has equivalent potency to 4-hydroxytamoxifen in terms of binding affinity to estrogen receptors, suppression of estrogen-dependent proliferation of breast cancer cells, and modulation of estrogen-mediated global gene expression [35, and references listed therein].

In vitro, these investigators have shown that endoxifen is formed primarily via 4-hydroxylation of the primary tamoxifen metabolite, N-desmethyltamoxifen, by the CYP2D6 enzyme.[36] Consistent with these in vitro findings, the steady-state endoxifen plasma concentrations during tamoxifen treatment were substantially reduced in women who carry CYP2D6 genetic variants or coprescribed CYP2D6 inhibitors.[33,37,38] More importantly, the steady-state plasma concentrations of endoxifen that are achieved at 4 months after tamoxifen therapy[37] were on average 10-fold higher than those of 4-hydroxytamoxifen, with a large degree of interpatient variability (up to 100-fold greater endoxifen exposure relative to 4-hydroxytamoxifen in some patients).[33,37,38] Given that CYP2D6 is an important pathway in the formation of endoxifen and that this metabolite contributes importantly to the in vitro activity of tamoxifen, it is logical to suggest that endoxifen predicts outcome.

In these studies, the investigators noted some variability in the endoxifen plasma concentration, which remains unexplained even after correction for CYP2D6 genotype and medication history.[33,37,38] Endoxifen plasma concentrations are likely to be dependent not only on its formation by CYP2D6, but also on its clearance by phase II enzymes.

Recent in vitro data suggest that endoxifen is predominantly O-glucuronidated by the UDP-glucuronosyltransferase (UGT) 2B7 enzyme.[39] Accordingly, a common mis-sense SNP resulting in a His>Tyr amino acid change at residue 268 of the UGT2B7 enzyme was recently shown to be associated with altered glucuronidation activity against endoxifen, with the UGT2B7268Tyr variant isoform (encoded by the UGT2B7*2 allele) exhibiting significantly decreased activity.[40] Therefore, it is now hypothesized that differences in UGT2B7 and in combination with CYP2D6 contribute to tamoxifen response.

Two recent reviews and two editorials summarized the current status regarding CYP2D6 polymorphisms, metabolites, and clinical outcomes.[35,41-43] Approximately eight studies in Caucasian and Asian patients have suggested that CYP2D6 intermediate or poor metabolizer allelic status is associated with poorer outcomes in prevention, adjuvant, and metastatic settings, and three studies have suggested the reverse.[44-54] Both reviews note the absence of studies in which CYP2D6 genotype and endoxifen levels have been studied with clinical outcomes and call for validation studies, in particular noting, “Investigating a direct relationship of endoxifen plasma concentration with clinical outcome is imperative.”[41,42] Unlike circumstances in Caucasians, the most frequent CYP2D6 allele in Asians is CYP2D6*10.

In summary, the pharmacogenetics of tamoxifen are incompletely understood, and the primary hypothesis that has emerged-that concentrations of the endoxifen metabolite are related to clinical outcomes-needs to be evaluated in the context of a prospective clinical trial.

Ethical Issues in Ovarian Suppression vs Ablative Treatment

In metastatic hormone receptor–positive breast cancer, treatments with LHRH agonists and surgical oophorectomy are associated with similar outcomes.[55,56] The data on this adjuvant comparison in premenopausal women are too limited and indirect to reach a conclusion, but there is no reason to expect incomparability, except on the question of the duration of LHRH therapy.[15,28]

From the time of the first meta-analysis report suggesting that adjuvant ovarian ablation (by surgery or radiation therapy) as practiced in the 1970s was, contrary to previous beliefs, likely to be effective, the practice in high-income countries has been to use LHRH agonists to achieve the “same” outcomes-ovarian function suppression and chronic tumor growth factor reduction.[57] On the benefit side for LHRH treatment, reversibility is touted as important. This benefit is less certain when the question of optimal duration of therapy is considered. In prostate cancer, clinicians often continue LHRH therapy indefinitely. On the cost side for LHRH agonists, inconvenience and the need to assess for biologic effect are practical considerations, tied together with the major issue of economic cost. At $500 or more per month, a year of LHRH treatment is $6,000 in direct costs, leading to costs of $18,000 and $30,000 for 3 and 5 years of therapy, respectively.

The limited surgical oophorectomy data have allowed this LHRH approach to be promulgated as the standard of care worldwide, a standard that is not practical for the majority of women who need treatment. In the face of the available data, it is inappropriate and ethically untenable to continue this stance. Surgical oophorectomy should be the global standard of care for premenopausal women with hormone receptor–positive tumors.

Primary Tumor Removal and ‘Surgical Stress’ in Solid Tumor Management

For many years it has been known that removal of primary tumors is associated with facilitation of the growth of micrometastatic disease. Hrushesky and colleagues have highlighted the often observed increase and peak in hazard for the appearance of clinical metastatic disease in the immediate 2 to 3 years following removal of primary breast cancers. These investigators hypothesized that perioperative factors can be manipulated to decrease this hazard.[58] Despite confirming data in various studies that this hazard peak is not a statistical artifact and must be anchored by the event of primary tumor removal, primary breast surgery has continued to be seen as a technical intervention.

REFERENCE GUIDE

Therapeutic Agents
Mentioned in This Article

Anastrozole (Arimidex)
Cyclophosphamide
Doxorubicin
Fluorouracil (5-FU)
Methotrexate
Tamoxifen
Zoledronic acid (Zometa)

Brand names are listed in parentheses only if a drug is not available generically and is marketed as no more than two trademarked or registered products. More familiar alternative generic designations may also be included parenthetically.

Exploratory early and longer-term data have suggested that concurrent (same day) surgical oophorectomy and primary breast surgery is characterized by significant benefit from oophorectomies done in the luteal phase of the menstrual cycle.[59,60] We have offered a “progesterone trigger hypothesis” to explain this observation: Rapid decreases in progesterone blood levels in the luteal phase of the menstrual cycle with oophorectomy lead to “downstream” angiogenic protein changes that block micrometastatic growth.[61] A recent elegant laboratory research report has offered complementary evidence that perioperative, proangiogenic surgical stress–induced changes can be manipulated with reductions in tumor growth.[62] These observations all strongly suggest that greater attention to perioperative tumor biology growth models is warranted. We have two phase III proof-of -principle clinical trials in breast cancer testing our oophorectomy timing hypothesis.

Conclusions

The descriptive epidemiology of breast cancer-in terms of global case burdens, now predominantly an Asian and premenopausal disease-and the realization that the majority of the available biologic and treatment data come from high-income populations with northern European genetic backgrounds, should temper our discussions of breast cancer treatment. Tumor specimen selection and management before hormonal receptor testing are critical in influencing the likelihood of finding the presence of estrogen and progesterone receptor proteins. Both clinicians and patients should view hormone receptor–positive breast cancer as a commonly chronic disease.

In premenopausal women, combined hormonal therapy with ovarian ablation or suppression and tamoxifen therapy is the standard of care, and the ongoing SOFT and TEXT studies are very unlikely to provide support otherwise. The pharmacogenetic data with respect to tamoxifen are currently insufficient to dictate clinical practice. Specific prospective trials investigating the hypothesis that endoxifen concentrations in individual patients predict therapeutic efficacy are urgently needed. The high economic cost of LHRH treatment compared to that of surgical oophorectomy, given repeatedly demonstrated comparability of therapeutic effects, suggest that surgical treatment should be the standard of care. Finally, perioperative primary tumor biology warrants significantly more attention as we seek better approaches to breast cancer control that are practical and inexpensive, and produce limited side effects.

References:

References

1. Ramo JC: The age of the unthinkable, p 11. New York; Little, Brown; 2009.

2. Pritchard KI: Ovarian supprerssion/ablation in premenopausal ER-positive breast cancer patients: Issues and recommendations. Oncology (Williston Park) 23:27-47 (incl discussion), 2009.

3. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase no 5, version 2.0. Lyon, France; IARC Press; 2004.

4. Curado MP, Edwards B, Shin HR, et al (eds): Cancer incidence in five continents, vol IX. IARC scientific publications no. 160. Lyon, France; IARC Press; 2007.

5. Love RR: Defining a global research agenda for breast cancer. Cancer 113:2366-2371, 2008.

6. Olopade F, Grushko TA, Nanda R, et al: Advances in breast cancer: Pathways to personalized medicine. Clin Cancer Res 14:7988-7999, 2008.

7. Tan S-H, Lee S-C, Goh B-C, et al: Pharmacogenetics in breast cancer therapy. Clin Cancer Res 14:8027-8041, 2008.

8. Uy GB, Laudico AV, Fernandez AM, et al: Immunohistochemical assay of hormone receptors in breast cancer at The Philippine General Hospital: Importance of early fixation of specimens. Philipp J Surg Spec 62:123-127, 2007.

9. Shen Y-C, Change C-J, Hsu C, et al: Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: Implications for age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev 14:1986-1990, 2005.

10. Goldstein NS, Hewitt SM, Taylor CR, et al: Recommendations for improved standardization of immunohistochemistry. App Immunohistochem Mol Morphol 15:124-133, 2007.

11. Werner M, Chott A, Fabiano A, et al: Effect of formalin tissue fixation and processing in immunohistochemistry. Am J Surg Pathol 24:1016-1019, 2000.

12. Goldstein NS, Ferkowicz M, Odish E, et al: Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Path 120:86-92, 2003.

13. Mann GB, Fahey VD, Feleppa F, et al: Reliance on hormone receptor assay of surgical specimens may compromise outcomes in patients with breast cancer. J Clin Oncol 23:5148-5154, 2005.

14. Uy GB, Laudico AV, Carnate JM, et al: Breast cancer hormone receptor assay results from core needle biopsy and modified radical mastectomy specimens from the same patients. Clin Breast Cancer 10(2), 2010.

15. Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.

16. Saphner T, Tormey DC, Gray R: Annual hazard rates recurrence for breast cancer afterprimary therapy. J Clin Oncol 14:2738-2746, 1996.

17. Goss PE, Ingle JN, Pater JL: Late extended adjuvant treatment with letrozole improves outcome in women with early stage breast cancer completing 5 years of tamoxifen. J Clin Oncol 26:1948-1955, 2008.

18. Hess KR, Pusztai L, Budzar AU, et al: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78:105-118, 2003.

19. Love RR, Dinh NV, Quy TT, et al: Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women. J Clin Oncol 26:253-257, 2008.

20. Mamounas EP, Jeong J-H, Wickerham DL, et al: Benefit from exemestane as extended adjuvant therapy following five years of adjuvant tamoxifen. J Clin Oncol 26:1965-1971, 2008.

21. Gray RG, Rea DW, Handley A, et al: aTTom (adjuvant Tamoxifen-To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor positive (ER+) or ER untested breast cancer-preliminary results (abstract 513). J Clin Oncol 26(15S):10s, 2008.

22. Peto R, Davies C: ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women. Preliminary results. Late breaking abstract presentation. San Antoinio Breast Cancer Symposium; San Antonio, Texas; December 14, 2007.

23. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009.

24. Klijn JG, Beex LV, Mauriac L, et al: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 92:903-911, 2000.

25. Klijn JG, Blamey RW, Boccardo F, et al: Combined tamoxifen and luteinizing hormone (LHRH) agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001.

26. Davidson NE, O’Neill AM, Vukov AM, et al: Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer. Results from INT 0101 (E5188). J Clin Oncol 23:5973-5982, 2005.

27. Ingle JN, Krook JE, Green SJ, et al: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic brerast cancer. J Clin Oncol 16:3439-3460, 1998.

28. Cusick J, Ambroisine L, Davidson N, et al: Use of luteinising hormone releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone receptor positive breast cancer: A meta-analysis of individual patient data from randomized adjuvant trials. Lancet 369:1711-1723, 2007.

29. Robert NJ, Wang M, Cella D, et al: Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer ≤ 3 cm (abstract 16). Proc Am Soc Clin Oncol 22:5, 2003.

30. Jakecz R, Hausmaninger H, Kubista E, et al: Randomized adjuvant trial of tamoxifen and goserilin versus cyclophosphamide, methotrexate, and fluoruracil: evidence for the superiority of treatment with endocrine blcoikagde in premenopausal patients with hormone responsive breast cancer. J Clin Oncol 20:4621-4627, 2002.

31. Jonat W, Kaufmann M, Sauerbrei W, et al: Goserelin versus cyclophosphamide, methotrexate, and flurouracil as adjuvant therapy in premenopausal women with node positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628-4635, 2002.

32. Jordan VC, Collins MM, Rowsby L, et al: A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305-316, 1977.

33. Stearns V, Johnson MD, Rae JM, et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:758-1764, 2003.

34. Johnson MD, Zuo H, Lee KH, et al: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159, 2004.

35. Desta Z, Flockhart DA: Germline pharmacogenetics of tamoxifen response: Have we learned enough? J Clin Oncol 25:5147-5149, 2007.

36. Desta Z, Ward BA, Soukhova NV, et al: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310:1062-1075, 2004.

37. Jin Y, Desta Z, Stearns V, et al:CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39, 2005.

38. Borges S, Desta Z, Li L, et al: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74, 2006.

39. Sun D, Sharma AK, Dellinger RW, et al: Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 35:2006-2014, 2007.

40. Blevins-Primeau AS, Sun D, Chen G, et al: Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 69:1892-1900, 2009.

41. Tan S-H, Lee S-C, Goh B-C, et al: Pharmacogenetics in breast cancer therapy. Clin Cancer Res 24:8027-8041, 2008.

42. Dezentjé VO, Guchelaar HJ, Nortier JW, et al: Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 15:15-21, 2009.

43. Hayes DF, Stearns V, Rae J, et al: A model citizen? Is tamoxifen more effective than aromatase inhibitor if we pick the right patients? J Natl Cancer Inst 100:610-613, 2008.

44. Goetz MP, Rae JM, Suman VJ, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318, 2005.

45. Goetz MP, Knox SK, Suman VJ, et al: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121, 2007.

46. Schroth W, Antoniadou L, Fritz P, et al: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193, 2007.

47. Gonzales-Santiago S, Zarate R, Haba-Rodriguez J, et al: CYP2D6*4 polymorphisms as a blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen. (abstract 590) J Clin Oncol 25(18S):25s, 2007.

48. Kiyotani K, Mushiroda T, Sas M, et al: Impact of CYP2D6*10 on recurrence free survival in breast cancer patientsreceiving adjuvant tamoxifen therapy. Cancer Sci 99:995-999, 2008.

49. Xu Y, Sun Y, Yao L, et al: Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 19:1423-1429, 2008.

50. Lim HS, Ju LH, Seok LK, et al: Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharamacokinetics in metastatic breast cancer. J Clin Oncol 25:3837-3845, 2007.

51. Bonanni B, Macis D, Maisonneuve P, et al: Polymorphism in the CYP2D6 tamoxifen metabolizing gene influences clinical effect but not hot flashes: Data from the Italian Tamoxifen Trial. J Clin Oncol 24:3708-3709, 2006.

52. Nowell SA, Ahn J, Rae JM, et al: Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249-258, 2005.

53. Wegman P, Vainikka L, Stal O, et al: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res Treat 7:R284-R290, 2005.

54. Wegman P, Elingarami S, Carstensen J, et al: Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res Treat 9:R7, 2007.

55. Taylor CW, Green S, Dalton WS, et al: Multicenter randomized climnical trial of goserilin versus surgical oophorectomy in premenopausal patients with receptor positive metastatic brast cancer: An intergroup study. J Clin Oncol 16:994-999, 1998.

56. Boccardo F, Rubagotti A, Perrotta A, et al: Ovarian ablation versus goserilin with or without tamoxifen in pre-menopausal patientsd with advanced breast cancer: Results of a multicentric Italian study. Ann Oncol 5:337-342, 1994.

57. Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 339:1-15, 71-85, 1992.

58. Retsky MW, Demicheli R, Swartzendruber DE, et al: Computer simulation of a breast cancer metastasis model. Breast Cancer Res Treat 45:193-202, 1997.

59. Love RR, Duc NB, Dinh NV, et al: Mastectomy and oophorectomy by menstrual cycle phase in operable breast cancer. J Natl Cancer Inst 94:662-669, 2002.

60. Love RR, Young GS, Hade EM, et al: Timing of adjuvant surgical oophorectomy in the menstrual cycle of premenopausal women with breast cancer and survival. Cancer. In press.

61. Love RR, Niederhuber JN: Models of breast cancer growth and investigations of adjuvant oophorectomy. Ann Surg Oncol 11:818-828, 2004.

62. Lee J-W, Shazad MMK, Lin YG, et al: Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 15:2695-2702, 2009.